成都治疗脉管炎要多久成都市专治静脉曲张医院,成都有什么医院看老烂腿的,成都脉管炎好治疗吗,成都治疗肝血管瘤在哪家医院好一点,成都哪里看血管瘤好,成都血管瘤去哪里治疗,成都前列腺肥大治疗费用

ALMATY, Nov. 4 (Xinhua) -- Kazakhstan's Center for Prevention and Control of AIDS said Friday that the country had 17,266 registered HIV carriers as of Oct. 1,compared with 15,908 as of Feb. 1, 2010.Of the HIV-positive people, 1,432 were diagnosed with AIDS while 1,110 people carrying the virus AIDS have died, the center said.Last year, it said, a total of 1,969 new HIV cases were reported in the country.

BEIJING, Dec. 4 (Xinhua) -- Acclaimed orthopaedic surgeons and experts attending a major conference in Beijing have agreed to build up a platform for international cooperation aiming at jointly coping with medical and social challenges.At the Sixth International Congress of the Chinese Orthopaedic Association (COA) that concluded on Sunday, presidents of more than 80 national and international orthopaedic societies signed a declaration which seeks a model for both developing and developed countries to help reduce medical costs in the aftermath of the global financial crisis.With an aging global population, rapidly rising medical costs have become a heavy financial burden for governments worldwide. Medical insurance cost control has become a hot topic around the world.Bone and joint diseases, infections due to traffic accident traumas and other diseases causing high disability rates have affected millions of people worldwide."One of the objectives of the COA international conference is to provide a platform for medical experts around the world to discuss not only clinical techniques but also medical and social problems," said Professor Wang Yan, chairman of the COA.To fully leverage existing professional knowledge and resources, presidents of orthopaedic organizations attending the conference adopted and released the Beijing Declaration which calls for a platform to enhance global and national collaboration and partnerships among the professions, industries and related patient organizations and disciplines.The declaration also stresses maximizing Internet-based learning and encouraging international exchanges."Worldwide, I have one lament, that we've spent so much money on medical research, but very little on orthopaedics. Most governments are more anxious to fund cancer or infectious diseases," said Professor Michael Huggness, president of the North American Spine Society."We think we're a bit handicapped by not having the money to pursue the research. As we get more sophisticated in our treatment, the price does go up. My expectation is that in another five to 10 years, we'll begin to apply some molecular techniques to assist us in healing. Maybe the price will come down when our knowledge base increases. But I think we'll just have to wait for a bit more research and a bit more basic science.""We definitely will... look into this issue of how we can have a suitably assigned budget from the government for orthopaedic care," said Professor K.M. Chan, from the Prince of Wales Hospital in Hong Kong."At the same time, we use evidence-based medicine to contain the medical cost in orthopaedics with very stringent monitors from the professions. That involves good-practice models, quality insurance and patient safety. With all these, we expect that the profession will be heading forward to join hands with the government to contain the cost."More than 15,000 surgeons, researchers and business representatives from China and abroad are attending the four-day annual conference to share the latest theories and techniques for curing musculoskeletal diseases as well as related social topics.Founded in 1980, the COA now has more than 30,000 registered members and is the largest sub-society of doctors under the Chinese Medical Association. The conference is the largest medical academic event in China.

SEOUL, Nov. 28 (Xinhua) -- Samsung Electronics, the world's second-largest manufacturer of mobile phones, said Monday that it launched its latest smart mobile gadget Galaxy Note in South Korea in a bid to take the lead in a new phase of the mobile phone market.The Galaxy Note, which was first introduced in September at IFA 2011, the consumer electronics fair held in Berlin, was Samsung's latest Galaxy lineup, combining the portability of a smartphone with the larger screen of a tablet computer, according to Samsung.The device ensured portability and grip with 9.65-millimeter thin, 182 grams in weight and a rounded back design, while featuring a 5.3-inch super active-matrix organic light-emitting diode (AMOLED) display.The function of "S Pen," or a digital pen, was added to the device in a bid to enable users to draw, paint and crop images by writing on the screen, Samsung said.Featuring Android's 2.3 Gingerbread platform, the gadget was powered by a 1.5-gigahertz dual core processor supplemented with fourth generation (4G) long term evolution (LTE) network service."Galaxy Note is a revolutionary product opening a new category in the market. It will deliver a whole new mobile experience beyond feature phones, smartphones and tablet devices," said Shin Jong-kyun, president and head of Samsung's mobile communications business.In addition, Samsung launched Galaxy Nexus, the world's first smartphone running Android's 4.0 Ice Cream Sandwich. The latest Android operating system (OS) combined the benefits of smartphones and tablet computers, according to Samsung.The smartphone, which was first introduced in Hong Kong last month, offered quicker multi-tasking and faster web browsing than previous models, while the near-field communication (NFC) function allowed users to easily share contents with other users by tapping their devices together, Samsung said.With the updated Ice Cream Sandwich, the Galaxy Nexus offered facial recognition technology, which unlocks the phone by identifying the user's face.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.